Precision immune regulation in KRAS-mutated cancers: the final piece of the puzzle?
Abstract In recent years, the development of targeted therapies for tumors with KRAS mutations has progressed rapidly, rendering the notion of KRAS as “undruggable” outdated. However, targeted therapies for KRAS mutations still face numerous challenges, including resistance, efficacy concerns, toxic...
Saved in:
| Main Authors: | Shenao Fu, Jiayao Ma, Changjing Cai, Jun Tan, Xiangying Deng, Hong Shen, Shan Zeng, Yihong Chen, Ying Han |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-07-01
|
| Series: | Journal of Experimental & Clinical Cancer Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13046-025-03444-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Mechanistic Foundations of KRAS‐Driven Tumor Ecosystems: Integrating Crosstalk among Immune, Metabolic, Microbial, and Stromal Microenvironment
by: Jiayao Ma, et al.
Published: (2025-08-01) -
A Phase 1/1B Trial of Pembrolizumab and Trametinib in Advanced NSCLC Enriched for KRAS Mutations
by: Jonathan W. Riess, MD, MS, et al.
Published: (2025-06-01) -
The efficacy of immunotherapy in non-small cell lung cancer with KRAS mutation: a systematic review and meta-analysis
by: Rui Zhao, et al.
Published: (2024-11-01) -
The role of KRAS and NRAS mutation detection in determining the therapy strategy for colorectal cancer
by: A. N. Toropovskiy, et al.
Published: (2022-11-01) -
Drugging the ‘undruggable’ KRAS: breakthroughs, challenges, and opportunities in pancreatic cancer
by: Nawaz Khan, et al.
Published: (2025-07-01)